Literature DB >> 6333271

Human myeloid leukemic cell (HL-60) autostimulator: relationship to colony-stimulating factor.

S L Perkins, P E Andreotti, S K Sinha, M C Wu, A A Yunis.   

Abstract

The human promyelocyte leukemic cell line HL-60 secretes a glycoprotein factor which stimulates HL-60 and myeloid cell growth and colony formation in vitro. Functional and biochemical studies indicate this autostimulatory activity (ASA) is distinct from colony-stimulating factor (CSF) activities reported previously. Human CSF I, CSF II, and HL-60 ASA stimulated HL-60 growth and colony formation. The ASA also demonstrated CSF activity for both granulocyte and macrophage colonies when assayed on normal mouse and human bone marrow cells. The ASA glycoprotein was partially purified 1200-fold to an apparent molecular weight of 25,000 on G-75 filtration and a pl of 4.9 after neuraminidase treatment. Serological cross-reactivity between human CSF I and HL-60 ASA was detectable by immune precipitation and neutralization of biological activity with rabbit anti-CSF I antibodies. The cross-reactive anti-CSF I antibodies also inhibited spontaneous HL-60 colony formation in vitro in the absence of exogenous CSF, ASA, or anti-HL-60 antibody activity. These results indicate that HL-60 ASA is an endogenous growth factor similar to CSF that may be required for HL-60 growth in vitro.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333271

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

Review 1.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

2.  Secretion of transforming growth factor-beta by human myelogenous leukemic cells and its possible role in proliferation of the leukemic cells.

Authors:  K Komatsu; H Nakamura; K Shinkai; H Akedo
Journal:  Jpn J Cancer Res       Date:  1989-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.